220
Views
1
CrossRef citations to date
0
Altmetric
CASE REPORT

Successful Treatment of Atopic Dermatitis with a Predominant Nipple Involvement by Abrocitinib During COVID-19 Pandemic: A Case Report

ORCID Icon, , , , &
Pages 789-792 | Received 08 Jun 2023, Accepted 24 Jul 2023, Published online: 01 Aug 2023

References

  • Williams HC, Burney PG, Hay RJ, et al. The UK working party’s diagnostic criteria for atopic dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. Br J Dermatol. 1994;131(3):383–396.
  • Wollenberg A, Wetzel S, Burgdorf WH, Haas J. Viral infections in atopic dermatitis: pathogenic aspects and clinical management. J Allergy Clin Immunol. 2003;112(4):667–674. doi:10.1016/j.jaci.2003.07.001
  • Magierska A, Ptak O, Szczepaniak Z, Gomułka K. Exacerbation of atopic dermatitis skin lesions in SARS-CoV-2 disease. Postepy Dermatol Alergol. 2022;39(5):998–1000. doi:10.5114/ada.2022.120893
  • Song HS, Jung SE, Kim YC, Lee ES. Nipple eczema, an indicative manifestation of atopic dermatitis? A clinical, histological, and immunohistochemical study. Am J Dermatopathol. 2015;37(4):284–288. doi:10.1097/DAD.0000000000000195
  • Kaur A, Kumar R, Gupta S. Nipple eczema in an adolescent girl presenting with persistent unilateral nipple discharge. BMJ Case Rep. 2020;13(8):e237691. doi:10.1136/bcr-2020-237691
  • Julián-Gónzalez RE, Orozco-Covarrubias L, Durán-McKinster C, Palacios-Lopez C, Ruiz-Maldonado R, Sáez-de-ocariz M. Less common clinical manifestations of atopic dermatitis: prevalence by age. Pediatr Dermatol. 2012;29(5):580–583. doi:10.1111/j.1525-1470.2012.01739.x
  • Shi M, Zhang H, Chen X, et al. Clinical features of atopic dermatitis in a hospital-based setting in China. J Eur Acad Dermatol Venereol. 2011;25(10):1206–1212. doi:10.1111/j.1468-3083.2010.03953.x
  • Beltrani VS. The clinical spectrum of atopic dermatitis. J Allergy Clin Immunol. 1999;104(3 Pt 2):S87–S98. doi:10.1016/S0091-6749(99)70050-3
  • Szalus K, Trzeciak M, Nowicki RJ. JAK-STAT inhibitors in atopic dermatitis from pathogenesis to clinical trials results. Microorganisms. 2020;8(11):1743. doi:10.3390/microorganisms8111743
  • Werfel T, Allam JP, Biedermann T, et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol. 2016;138(2):336–349. doi:10.1016/j.jaci.2016.06.010
  • Chovatiya R, Paller AS. JAK inhibitors in the treatment of atopic dermatitis. J Allergy Clin Immunol. 2021;148(4):927–940. doi:10.1016/j.jaci.2021.08.009
  • Gooderham MJ, Forman SB, Bissonnette R, et al. Efficacy and safety of oral janus kinase 1 Inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial. JAMA Dermatol. 2019;155(12):1371–1379. doi:10.1001/jamadermatol.2019.2855
  • Eichenfield LF, Flohr C, Sidbury R, et al. Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: the JADE TEEN randomized clinical trial. JAMA Dermatol. 2021;157(10):1165–1173. doi:10.1001/jamadermatol.2021.2830
  • Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, Phase 3 trial. Lancet. 2020;396(10246):255–266. doi:10.1016/S0140-6736(20)30732-7
  • Santa Cruz A, Mendes-Frias A, Oliveira AI, et al. Interleukin-6 is a biomarker for the development of fatal severe acute respiratory syndrome coronavirus 2 Pneumonia. Front Immunol. 2021;12:613422. doi:10.3389/fimmu.2021.613422
  • Klimek L, Pfaar O, Worm M, et al. Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic: position paper of Ärzteverband Deutscher Allergologen (AeDA)(A), Deutsche Gesellschaft für Allergologie und Klinische Immunologie (DGAKI)(B), Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA)(C), Österreichische Gesellschaft für Allergologie und Immunologie (ÖGAI)(D), Luxemburgische Gesellschaft für Allergologie und Immunologie (LGAI)(E), Österreichische Gesellschaft für Pneumologie (ÖGP)(F) in co-operation with the German, Austrian, and Swiss ARIA groups(G), and the European Academy of Allergy and Clinical Immunology (EAACI)(H). Allergol Select. 2020;4:53–68. doi:10.5414/ALX02166E
  • Ricardo JW, Lipner SR. Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during the COVID-19 pandemic. Dermatol Ther. 2020;33(5):e13687. doi:10.1111/dth.13687
  • Miodońska M, Bogacz A, Mróz M, Mućka S, Bożek A. The effect of SARS-CoV-2 virus infection on the course of atopic dermatitis in patients. Medicina. 2021;57(6):521. doi:10.3390/medicina57060521